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Abstract
The anabolic potential of a dietary protein is determined by its ability to elicit postprandial rises in circulating essential amino acids and insulin.
Minimal data exist regarding the bioavailability and insulinotropic effects of non-animal-derived protein sources. Mycoprotein is a sustainable
and rich source of non-animal-derived dietary protein. We investigated the impact of mycoprotein ingestion, in a dose–response manner,
on acute postprandial hyperaminoacidaemia and hyperinsulinaemia. In all, twelve healthy young men completed five experimental trials in
a randomised, single-blind, cross-over design. During each trial, volunteers consumed a test drink containing either 20 g milk protein (MLK20)
or a mass matched (not protein matched due to the fibre content) bolus of mycoprotein (20 g; MYC20), a protein matched bolus of
mycoprotein (40 g; MYC40), 60 g (MYC60) or 80 g (MYC80) mycoprotein. Circulating amino acid, insulin and uric acid concentrations, and
clinical chemistry profiles, were assessed in arterialised venous blood samples during a 4-h postprandial period. Mycoprotein ingestion
resulted in slower but more sustained hyperinsulinaemia and hyperaminoacidaemia compared with milk when protein matched, with overall
bioavailability equivalent between conditions (P> 0·05). Increasing the dose of mycoprotein amplified these effects, with some evidence of a
plateau at 60–80 g. Peak postprandial leucine concentrations were 201 (SEM 24) (30min), 118 (SEM 10) (90min), 150 (SEM 14) (90min), 173
(SEM 23) (45min) and 201 (SEM 21 (90min) µmol/l for MLK20, MYC20, MYC40, MYC60 and MYC80, respectively. Mycoprotein represents
a bioavailable and insulinotropic dietary protein source. Consequently, mycoprotein may be a useful source of dietary protein to stimulate
muscle protein synthesis rates.
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A growing body of research suggests that increasing dietary
protein consumption beyond currently recommended amounts,
that is 0·75–0·8g/kg body weight/d in the UK/USA(1,2); can aid in
the maintenance/gain of skeletal muscle mass, optimise tissue
reconditioning in response to exercise, and/or promote cardio-
metabolic health and weight management(3–6). Consequently,
recommendations to increase dietary protein consumption in
various populations, such as older adults, athletes, and those at
risk of metabolic disease, are beginning to emerge(3–6). However,
this trend is occurring in the face of mounting challenges asso-
ciated with the sustainability of increased production of animal
proteins(7). As a result, nutritional research is beginning to address
the efficacy of alternative, plant-based protein sources(8,9).
Mycoprotein, a food source produced by continuous
fermentation of the filamentous fungus Fusarium venenatum,
represents an alternative dietary protein source which, com-
pared with animal-derived sources, imposes a significantly
lower environmental burden(10–13). Interestingly, previous work
has shown benefits of mycoprotein consumption on blood
cholesterol and lipid profiles, satiety and glycaemic control in
both healthy and metabolically compromised individuals(13–18).
However, the potential for mycoprotein to support muscle mass
maintenance and/or reconditioning remains to be investigated.
Physiological regulation of skeletal muscle mass is controlled
in large part by dietary protein intake(19). Dietary protein
ingestion increases muscle protein synthesis rates and, to a
lesser extent, inhibits muscle protein breakdown rates, thereby
allowing net muscle protein accretion (the ‘anabolic response’).
The postprandial elevation in muscle protein synthesis rates
is driven by the rise in plasma essential amino acids(20) and
leucine in particular(21,22), whereas the inhibition of protein
breakdown is mainly attributed to hyperinsulinaemia(23,24).
These postprandial periods offset the net loss of muscle protein
which occurs during fasting periods. Accordingly, the potential
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utility (and amount required) of a specific dietary protein
to support the maintenance, gain or reconditioning of muscle
tissue is contingent on its ability to mount a sufficient anabolic
response. The anabolic response, in turn, is dependent upon
the dietary proteins bioavailability and insulinotropic proper-
ties. To date, data concerning these postprandial plasma
profiles following mycoprotein ingestion are not available.
Mycoprotein is also a source of dietary purines, primarily present
as nucleic acids. It has been proposed that dietary nucleic acid
consumption should be limited due to concerns that excessive
consumption can result in elevated serum uric acid concentra-
tions(25–27), the latter representing an independent risk factor for the
development of gout and an indicator of type 2 diabetes(28)
However, these recommendations are based on studies that have
fed large quantities of isolated, or yeast derived, nucleic acids
above levels likely to be found under normal nutritional condi-
tions(29,30). Such findings require corroboration following the
ingestion of nucleic acid containing whole food sources.
The aim of the present study was to provide a detailed acute
postprandial plasma hyperaminoacidaemic and hyper-
insulinaemic profile in response to the ingestion of graded
quantities of mycoprotein compared with a reference, animal-
derived protein source (milk protein). Due to mycoprotein
naturally possessing a large fibre content, we chose to compare
with milk protein on a gram for gram total food (i.e. mass
matched) and gram for gram total protein (i.e. protein matched)
basis. We hypothesised that hyperaminoacidaemia and hyper-
insulinaemia would be more rapid with milk protein, though
bioavailability of amino acids would be similar between protein
sources, and increase in accordance with dose. As a secondary
aim, we investigated the acute circulating serum uric acid
and plasma clinical chemistry responses to the ingestion of
increasing doses of mycoprotein.
Methods
Subjects and medical screening
We recruited fifteen healthy young men to participate in the
present study. Before inclusion in the study, subjects completed a
routine medical screening to ensure suitability for acceptance
onto the study. This screening involved the determination of
height, weight, BMI, resting blood pressure and body composi-
tion. Body fat and lean mass were determined by Air Displace-
ment Plethysmography (BodPod; Life Measurement, Inc.). During
the screening, subjects also completed a general health ques-
tionnaire. Exclusion criteria were a BMI below 18·5 or above
30kg/m2, regular smoker, type 2 diabetes mellitus or CVD/com-
plications. Following screening, three subjects either declined to
participate or did not fit the inclusion criteria meaning that twelve
healthy young (age: 28 (SEM 2) years; BMI: 26 (SEM 1) kg/m2) men
were ultimately included in the present study. All subjects com-
pleted all aspects of the study and so all data throughout repre-
sent n 12. Included subjects’ characteristics and habitual diet are
presented in Table 1. Subjects were also instructed to cease taking
any nutritional supplements for 2 weeks before the study and
until all study visits were completed. During the screening, sub-
jects were provided with a 3-d food diary and were instructed by
a nutritionist in how to complete the diary in as much detail as
possible. Food and drink intake was recorded for 3 consecutive
days including 2 week days and 1 weekend day. The habitual
energy and macro/micro-nutrient intake of the habitual diet was
subsequently calculated using dedicated nutritional software
(Nutritics Professional Nutritional Analysis Software). All subjects
were informed on the nature and risks of the experiment before
written informed consent was obtained. The study was approved
by the Department of Sport and Health Sciences, University of
Exeter’s Ethical Committee and conducted in accordance with the
Declaration of Helsinki.
Experimental overview and design
In a randomised, single-blind, cross-over design, subjects par-
ticipated in 5 laboratory test days. During each visit subjects
ingested a test drink containing 20 g milk protein (MLK20), a
‘mass matched’ bolus of mycoprotein (20 g; MYC20), a protein
matched bolus of mycoprotein (40 g; MYC40), or 60 g (MYC60)
or 80 g (MYC80) boluses of mycoprotein. Arterialised venous
blood samples were collected in the fasted state and at regular
intervals throughout a 4-h postprandial period to assess circu-
lating amino acid, insulin and uric acid concentrations, and
detail the plasma clinical chemistry profile. Indirect calorimetry
and visual analogue scales (VAS) were used at regular intervals
to determine whole body energy expenditure and subjective
appetite scores, respectively.
Experimental visits
An overview of the experimental setup for each test day is
illustrated in Fig. 1. Following inclusion into the study,
Table 1. Participants’ characteristics and habitual diet
(Mean values with their standard errors)
Mean SEM
Characteristics
Age (years) 28 2
Body mass (kg) 80 3
Height (cm) 177 2
BMI (kg/m2) 26 1
Lean mass (kg) 67 2
Body fat (%) 17 2
Fasting plasma glucose (mmol/l) 5·5 0·1
Fasting serum insulin (mU/l) 9·2 0·6
Systolic blood pressure (mmHg) 127 2
Diastolic blood pressure (mmHg) 78 2
Mean arterial pressure (mmHg) 93 2
RMR (kJ/d) 2278 48
Nutritional parameters
Energy intake (MJ/d) 9·4 0·6
Protein intake (g/d) 107 10
Protein intake (g/kg BW per d) 1·3 0·2
Habitual fat intake (g/d) 91 5
Carbohydrate intake (g/d) 259 28
Alcohol intake (g/d) 4 3
Protein intake (En%) 19 2
Fat intake (En%) 37 2
Carbohydrate intake (En%) 43 3
Alcohol intake (En%) 1 1
Caffeine intake (mg/d) 85 22
BW, body weight, En%, percentage of total energy intake.
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volunteers attended the laboratory on five separate occasions,
with each visit being separated by at least 3 d to ensure
complete digestion, absorption and metabolism of the test meal.
Volunteers were asked to abstain from strenuous physical
activity and alcohol consumption for at least 48 h before each
visit. For each test day, volunteers arrived at the laboratory at
08.30 hours in the fasted state, voided their bladder and rested
semi-supine on a hospital bed for 30min. Thereafter, resting
whole body metabolic rate was determined using expired gas
collections for indirect calorimetry via a mixing chamber which
obtained 20 s averages (Cortex Metalyzer 2R gas analyser;
Cortex). Expired gases were collected and recorded for a
15-min period, the last 5min of which were used to obtain
average V ̇O2 and V ̇CO2 values to determine substrate oxidation
rates according to the non-protein stoichiometric equations
detailed by Frayn(31). Total energy expenditure during this
period was calculated as the sum of energy production from fat
and carbohydrate, assuming that the oxidation of 1 g of TAG
(862 g/mol) liberates 39·4 kJ and 1 g of glucose (180 g/mol)
liberates 15·6 kJ of energy. This was then used to calculate
resting 24 h energy expenditure at this given time point.
Following this, volunteers completed a subjective appetite
VAS(32). These 100mm paper-based scales detailed questions
regarding fullness, hunger, satisfaction, prospective food con-
sumption and satiety which were anchored by diametrically
opposed feelings of extremity. Volunteers reported on each
scale their perceived feelings in the same order each time.
Ratings were subsequently measured by the same researcher
each time to minimise discrepancies and used to calculate an
appetite score as reported previously(32). A cannula was inser-
ted retrogradely into a superficial vein on the dorsal surface of
the hand. This hand was kept in a hand-warming unit (air
temperature 50–60oC) for 15min to arterialise the venous
drainage of the hand(33) after which a fasting (8ml) blood
sample was collected and a 2-ml flush of saline was used to
keep the cannula patent for further blood sampling. Thereafter,
volunteers ingested one of the test drinks (in a randomised,
counterbalanced for order and single-blind (the volunteer)
fashion) containing either MLK20, 20 (MYC20), MYC40, MYC60
or MYC80, within a total fluid volume of 650ml. Volunteers
were instructed to consume the test drink within 5min, with the
first visit providing the precise time to be repeated on sub-
sequent visits to minimise any effect that speed of consumption
may have on observed plasma amino acid kinetics. Completion
of drink consumption signified the beginning of a 4-h post-
prandial testing period. Further indirect calorimetry measure-
ments were taken for the final 15min of each hour (with the
final 5min used to determine energy expenditure as described
above) in order to quantify the thermic effect of protein
ingestion. Given the error in such indirect calorimetry mea-
surements being general accepted as 5–10%(34), we assumed
that we would detect a thermic effect of protein ingestion only if
the value increased by >10%. Further VAS scales were also
completed every 30min throughout the postprandial period.
Additional arterialised venous blood samples were collected
from the hand cannula at 15, 30, 45, 60, 90, 120, 150, 180, 210
and 240min into the postprandial period, with additional 2ml
saline flushes used after each. Following the final blood col-
lection the cannula was removed, volunteers were provided
with a meal, and were then free to leave the laboratory.
Test drink preparation and consumption
Isolated milk was obtained from a commercial supplier
(Mega Milk Protein 85; Hench Nutrition Ltd) and freeze-dried
mycoprotein was obtained for drink preparation from Marlow
Foods Ltd. For detailed safety and nutritional information
regarding the production and consumption of mycoprotein(35).
Test drinks were prepared by adding the requisite type/amount
of protein to 300ml water and 75ml non-energetic artificial
coconut or caramel flavouring (depending on volunteer
preference but maintained the same for all visits within an
individual; Jordan’s sugar free skinny syrups; The Protein Pick
and Mix Ltd) and mixing thoroughly using a food blender.
Water was then added to make up a total volume of 600ml and
mixed again. Following drink consumption by the volunteer an
additional 50ml of water was then added to ‘wash’ the bottle
and ensure all protein was consumed, making a total volume of
650ml consumed by a volunteer with each test drink. All
drinks were well tolerated, consumed within the allotted time
Blood sample
(min)
Time 
–30 0 60 120 240180
Protein ingestion
(20 g milk protein, or 20, 40, 60 or 80 g mycoprotein)
Fasting Postprandial test period
Indirect calorimetry
VAS
* * * * * * * * *
Fig. 1. Overview of the experimental protocol. VAS, visual analogue scale.
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(i.e. 5min) and no adverse effects, nauseas or sickness were
reported during or after the test day. Following ingestion of
each drink, volunteers were asked to identify which condition
they thought they had received which was noted down without
feedback. The overall success rate for volunteers correctly
identifying the condition was 69%. Individual condition
success rates were as follows: MLK20, 78%; MYC20, 67%;
MYC40, 78%; MYC60, 67%; MYC80, 56%. The nutritional
content and amino acid composition of the different drinks are
presented in Table 2.
Blood sample collection and analyses
Each blood sample, 4ml, was collected into EDTA containing
tubes (BD vacutainer LH; BD Diagnostics, Nu-Car) and cen-
trifuged immediately at 3000 g at 4°C for 10min. Blood plasma
was obtained, then aliquoted and frozen at –80°C for sub-
sequent analyses. The remaining 4ml of each blood sample was
collected into additional vacutainers (BD vacutainers SST II)
which were left to clot at room temperature for at least 60min
and then centrifuged at 3000 g and 21°C for 15min to obtain
blood serum. Serum was then removed and aliquoted before
freezing at –80°C for subsequent analyses.
Plasma amino acid profiles were determined via liquid
chromatography-MS. Full details of the methods used are pro-
vided in the online Supplementary material. In brief, proteins
were precipitated out from the samples. The supernatant was
then filtered and derivitised with the addition of stable isotope-
labelled amino acid internal standards ((L-amino acid mix;
Sigma-Aldrich Co.). Thereafter, HPLC-ESI-MS/MS quantitative
analysis of amino acids in plasma was performed using an
Agilent 6420B triple quadrupole (QQQ) mass spectrometer
(Agilent Technologies) hyphenated to a 1200 series Rapid
Resolution HPLC system (Agilent Technologies). Data analysis
was undertaken using Agilent Mass Hunter Quantitative analysis
software for QQQ (version B.07.01). Accurate quantification used
the stable isotope-labelled internal standards added during sam-
ple extraction.
Serum insulin concentrations were determined in duplicate
using a commercially available ELISA assay kit (Oxford Bio-
systems Ltd) with a within-batch CV of 3·2%. Serum uric acid
concentrations were determined enzymatically via colorimetry
(Cobas 8000 automated analyser; Roche Diagnostics) as
described previously(36) with a within-batch CV of 2·6%. Plasma
glucose, urea, creatinine and additional electrolyte/clinical
chemistry profiles were determined using an automated
analyser (Stat profile pHOx ultra analyzer; Nova Biomedical).
Statistical analyses and data presentation
Due to this being the first study dedicated to assessing the plasma
bioavailability of mycoprotein-derived amino acids in vivo fol-
lowing graded intakes, it was not possible to calculate an effect
size and therefore perform a statistical power analysis to calculate
the number of subjects required to observe significant effects. As
such, we chose the number of subjects required based on our
knowledge and experience of the variability in investigating the
bioavailability of plasma amino acids derived from alternate
dietary protein sources(22,37–39), coupled with our hypothesis that
a steep dose–response approach as used in the present study
would result in disparate plasma amino acid profiles.
All data are expressed as means with their standard errors.
Fasting and postprandial kinetic responses for each of the vari-
ables are displayed in two separate graphs to avoid congestion,
and present a clear comparison in one graph of MLK20 v. its
mass (MYC20) and protein (MYC40) matched conditions, and a
second graph allowing the mycoprotein dose–response rela-
tionship to be visualised (i.e. comparing MYC20, MYC40, MYC60
and MYC80). However, for all parameters, all five conditions
were compared within the same statistical test, and analysed with
a two-way ANOVA with repeated measures (with condition and
time as factors). In the event of a significant main effect,
Bonferroni post hoc tests were applied to locate individual
differences, with each postprandial value being compared with
the corresponding fasting value so the impact of protein inges-
tion within each condition could be evaluated. Where AUC were
calculated, a one-way ANOVA was performed to detect any
significant effect of treatment. If a significant main effect was
detected, multiple t tests were used to compare each condition
with each other. Plasma biochemistry profiles, indirect calori-
metry and VAS data were averaged as fasting, early postprandial
(average of all data collected within the first 2 h post protein
consumption) and late postprandial (average of all data collected
2–4h post protein consumption) responses and analysed with a
two-way ANOVA and Bonferroni post hoc tests as described
above. Statistical significance was set at P< 0·05. All calculations
Table 2. Nutritional content of the test drinks
MLK20 MYC20 MYC40 MYC60 MYC80
Macronutrient composition
Energy (kJ) 288 284 569 854 1138
Protein (g) 16 9 18 27 36
Fat (g) 0·2 3 5 8 10
Carbohydrate (g) 0·7 2 4 6 8
Fibre (g) 0·7 5 10 15 20
Amino acid content
Aspartic acid 1·2 1·0 1·9 2·9 3·8
Serine 0·8 0·4 0·9 1·3 1·8
Glutamic acid 3·2 1·1 2·2 3·4 4·5
Gly 0·3 0·4 0·9 1·3 1·7
His 0·4 0·2 0·4 0·7 0·9
Arg 0·5 0·6 1·3 1·9 2·5
Thr 0·7 0·5 1·0 1·5 2·0
Ala 0·5 0·6 1·2 1·7 2·3
Pro 1·5 0·4 0·9 1·3 1·8
Cys 0·6 0·6 1·2 1·7 2·3
Tyr 0·8 0·4 0·7 1·1 1·4
Val 1·0 0·5 1·1 1·6 2·2
Met 0·3 0·6 1·2 1·7 2·3
Lys 1·3 0·7 1·5 2·2 2·9
Ile 0·8 0·4 0·9 1·3 1·8
Leu 1·5 0·7 1·4 2·1 2·9
Phe 0·7 0·4 0·8 1·3 1·7
Trp 0·2 0·6 1·2 0·6 0·6
EAA 6·9 4·7 9·4 13·0 17·1
NEAA 9·4 5·5 11·1 16·6 22·1
BCAA 3·3 1·7 3·4 5·1 6·8
MLK20, 20 g milk protein; MYC20, 20 g mycoprotein; MYC40, 40 g mycoprotein;
MYC60, 60g mycoprotein; MYC80, 80 g mycoprotein; EAA, total essential amino
acids; NEAA, total non-essential amino acids; BCAA, total branched chain
amino acids.
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were performed by using GraphPad Prism version 7.0 (GraphPad
Software).
Results
Plasma amino acid concentrations
Fasting and postprandial plasma amino acid concentrations are
shown in Fig. 2 and 3. From similar fasting levels, plasma total
amino acid concentrations (Fig. 2(A) and (B)) increased with
protein ingestion (time effect: P< 0·0001) and by differing
degrees depending upon condition (time× treatment interac-
tion effect; P< 0·001). MLK20 exhibited the most rapid peak
concentration (30min) and remained elevated relatively briefly
for only 45min. Conversely, mycoprotein conditions generally
showed a more delayed rise to peak concentrations, with a
more sustained availability: MYC40, MYC60 and MYC80 peaked
between 45 and 120min, but stayed elevated above fasting
levels for between 120 and 240min. MYC20 did not show a
significant rise in postprandial total amino acid concentrations.
When expressed as an AUC (Fig. 2(C)), a significant treatment
effect on 4 h postprandial total amino acid availability was
detected (P< 0·05) indicating a dose–response effect, with
individual responses showing MYC60 and MYC80 were greater
when compared with MYC20 (both P< 0·05), and MYC80
greater when compared with MYC40 (P< 0·05).
Fasting levels of essential amino acids (Fig. 2(D) and (E))
were equivalent between conditions. Protein ingestion led to a
rise in plasma essential amino acid concentrations (time effect;
P< 0·0001) which differed across conditions (time× treatment
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Fig. 2. Plasma total (A and B), total essential (D and E) and total non-essential (G and H) amino acid concentrations in the fasting state (t= 0) and at regular intervals
during a 4-h postprandial period following the ingestion of 20 g milk protein (MLK20), or 20 g (MYC20), 40 g (MYC40), 60 g (MYC60) or 80 g (MYC80) mycoprotein in
healthy, young men (n 12). Values are means, with their standard errors represented by vertical bars. A, D, G: , MLK20; , MYC20; , MYC40 and B, E, H:
, MYC20; , MYC40; , MYC60; , MYC80. For each variable, data are separated into two graphs for clear comparison of relevant conditions, but all conditions
were statistically analysed together with two-way repeated measures ANOVA and Bonferroni post hoc tests applied to locate individual differences: a, b, c, d and e
indicate value different from corresponding fasting value for MLK20, MYC20, MYC40, MYC60 and MYC80 conditions, respectively. Data are also expressed as AUC
for the total 4 h postprandial responses for total (C), essential (F) and non-essential (I) amino acids. Data were analysed for a main effect with a one-way ANOVA and
individual t tests were applied to locate individual differences: a, b, c and d indicate value different from value for MLK20, MYC20, MYC40 and MYC60 conditions,
respectively.
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interaction; P< 0·05). Specifically, plasma essential amino acid
concentrations increased briefly from 30 to 45min in MLK20
(P< 0·05), were unaffected in MYC20 (P> 0·05) and increased
in a more sustained manner (but less rapidly compared with
MLK20) in MYC40 (from 60 to 120min; P< 0·05), MYC60 (from
45 to 180min; P< 0·05) and MYC80 (from 45 to 240min;
P< 0·05). The AUC of the essential amino acid response
(Fig. 2(F)) to protein ingestion showed an effect of treatment
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(P< 0·05) indicating a dose–response relationship, with MYC60
and MYC80 conditions being significantly greater compared
with MYC20 (both P< 0·05).
From equivalent fasting values, plasma non-essential amino
acid concentrations (Fig. 2(G) and (h)) increased with protein
ingestion (time effect; P< 0·0001) in a varying manner
depending upon condition (time× treatment interaction;
P< 0·01). Specifically, MLK20 showed a sharp, transient rise
between 15 and 45min (P< 0·01) into the postprandial period,
MYC20 did not change, MYC40 displayed a relatively slower
increase (90–120min), whereas MYC60 and MYC80 exhibited
more sustained elevations (from 15 to 120 and 45 to 240min,
respectively (both P< 0·05)). Non-essential amino acid AUC
(Fig. 2(I)) also showed a significant dose–response relationship
(P< 0·05), with MYC60 showing a greater response compared
with MYC20 (P< 0·05) and MYC80 being higher than both
MYC20 (P< 0·05) and MYC40 (P< 0·05).
Plasma total branched chain amino acids (Fig. 3(A) and (B)),
from similar fasting values (MLK20: 488 (SEM 31) µmol/l, MYC20:
442 (SEM 51) µmol/l, MYC40: 459 (SEM 41) µmol/l, MYC60: 497
(SEM 57) µmol/l, MYC80: 526 (SEM 52) µmol/l), showed a
significant effect of time (P< 0·0001) and a time× treatment
interaction (P< 0·0001). Postprandial branched chain amino
acid concentrations in MLK20 were elevated above fasting
levels from 15 to 90min (P< 0·05) and peaked at 45min
(848 (SEM 102) µmol/l), did not change in MYC20 (though
numerically peaking at 90min; 581 (SEM 54) µmol/l), were
raised in MYC40 from 45 to 150min (P< 0·05) and peaking
at 120min (752 (SEM 80) µmol/l), and were elevated in MYC60
and MYC80 from 45 to 240min (P< 0·05), both peaking
at 120min (831 (SEM 109) and 943 (SEM 102) µmol/l,
respectively). Plasma postprandial branched chain amino acid
concentration AUC (Fig. 3(C)) showed a clear dose–response
relationship, with MYC20 displaying lower concentrations
than MLK20 (P< 0·05) and MYC40, MYC60 and MYC80
all showing greater responses compared with MYC20
(all P< 0·05), and MYC80 also significantly higher than
MLK20 (P< 0·05).
When examining the branched chain amino acids individually,
plasma leucine concentrations (Fig. 3(D) and (E)) were influ-
enced by protein ingestion (time effect: P< 0·0001) and condi-
tion (treatment effect: P< 0·05), and a significant time× condition
interaction (P< 0·0001) was also detected. Specifically, from
similar fasting levels (approximately 90 µmol/l), peak post-
prandial leucine concentrations increased to 201 (SEM 24)
(at 30min), 118 (SEM 10) (at 90min), 150 (SEM 14) (at 90min), 173
(SEM 23) (at 45min) and 201 (SEM 21) (at 90min) µmol/l for
MLK20, MYC20, MYC40, MYC60 and MYC80, respectively.
Individual responses of leucine were similar (but more pro-
nounced) to those observed for the above detailed sub-groups of
amino acids. Specifically, MYC20 did not show any individual
changes. MLK20 resulted in more rapid, but less sustained
leucinaemia (from 15 to 90min; P< 0·05) compared with all
mycoprotein conditions >20 g: MYC40, 45–150min (P< 0·05);
MYC60, 30–180min (P< 0·05); and MYC80, 45–240min
(P< 0·05). Postprandial leucine AUC (Fig. 3(F)) also showed a
clear dose–response relationship (P< 0·05). Specifically, the
postprandial leucine response in MYC20 was lower compared
with MLK20 (P< 0·05), and responses in MYC40, MYC60 and
MYC80 were all greater than MYC20 (all P< 0·05), and MYC80
also showing a higher level compared with MLK20 (P< 0·05) and
MYC40 (P< 0·05). Plasma isoleucine (time effect; P< 0·0001,
treatment; P< 0·05), interaction P< 0·0001) and valine (time
effect; P< 0·0001, treatment; P= 0·015, interaction P< 0·01)
showed similar main effects to leucine, with individual differ-
ences, peaks, concentrations and AUC illustrated in Fig. 3(G)–(L)).
Serum insulin concentrations
Fasting and postprandial serum insulin concentrations are
depicted in Fig. 4. Fasting levels did not differ between condi-
tions (MLK, 10·4 (SEM 1·9)mU/l; MYC20, 8·7 (SEM 1·2)mU/l;
MYC40, 8·9 (SEM 1·6)mU/l; MYC60, 8·9 (SEM 1·5)mU/l; MYC80,
9·0 (SEM 1·4)mU/l; P> 0·05). Significant effects of time
(P< 0·0001) and a treatment× time interaction (P< 0·0001)
were observed. MLK20 resulted in a rapid (at 15min) but brief
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Fig. 4. Serum insulin (A and B) concentrations in the fasting state (t= 0) and at regular intervals during a 4-h postprandial period following the ingestion of 20 g milk
protein (MLK20), or 20 g (MYC20), 40 g (MYC40), 60 g (MYC60) or 80 g (MYC80) mycoprotein in healthy, young men (n 12). Values are means, with their standard
errors represented by vertical bars. A: , MLK20; , MYC20; , MYC40 and B: , MYC20; , MYC40; , MYC60; , MYC80. Data are separated into two graphs
for clear comparison of relevant conditions, but all conditions were statistically analysed together with a two-way repeated measures ANOVA and Bonferroni post hoc
tests applied to locate individual differences: a, b, c, d and e indicate value different from corresponding fasting value for MLK20, MYC20, MYC40, MYC60 and MYC80
conditions, respectively. Data are also expressed as AUC for the total 4 h postprandial response (C). Data were analysed for a main effect with a one-way ANOVA and
individual t tests were applied to locate individual differences: a, b, c and d indicate value different from value for MLK20, MYC20, MYC40 and MYC60 conditions,
respectively.
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(until 30min; P< 0·001) rise in circulating insulin levels, which
returned to fasting levels after 45min. MYC20 did not alter
serum insulin concentrations, though MYC40, MYC60 and
MYC80 all increased circulating insulin concentrations at 15min
(all P< 0·05) and remained elevated until 60min (MYC40;
P< 0·01) to 90min (MYC60 and MYC80; P< 0·05). Peak insulin
concentrations were observed at 15min for the MLK20 (21·8 (SEM
4·1)mU/l), MYC20 (10·6 (SEM 1·6)mU/l) and MYC40
(16·2 (SEM 2·9)mU/l) conditions, and after 45min in MYC60 (19·3
(SEM 2·8)mU/l) and MYC80 (22·9 (SEM 3·2)mU/l), though the
magnitudes of the peaks did not differ (P> 0·05). When com-
paring the overall postprandial insulin response between
conditions as an AUC (peaks above baseline) (Fig. 4(C)) MYC20
was lower compared with all other conditions (P< 0·05). MLK20
was not different compared with MYC40, and MYC60 (P< 0·01)
and MYC80 (P< 0·01) showed greater responses compared with
MLK20, but were not different from MYC40 or from one another.
Serum uric acid concentrations
Serum uric acid concentrations in the fasting state and over a 4-h
postprandial period following protein ingestion are depicted in
Fig. 5. Fasting plasma uric acid concentrations were similar in all
conditions (MLK20, 338 (SEM 21) µmol/l; MYC20, 362 (SEM
17) µmol/l; MYC40, 354 (SEM 18) µmol/l; MYC60, 365 (SEM
20) µmol/l; MYC80, 350 (SEM 12) µmol/l; P> 0·05). There were
significant time (P< 0·0001), treatment (P< 0·01) and time×
treatment interaction (P< 0·0001) effects detected. In MLK20 and
MYC40 fasting plasma uric acid concentrations remained unal-
tered across the postprandial period. MYC20 had minimal impact
on serum uric acid concentrations, though there was a significant
decrease at 150min (P< 0·05) only. With MYC60 uric acid con-
centrations increased modestly by 30min (P< 0·05), and
remained elevated until 150min before returning to fasting
values, with the peak concentration of 387 (SEM 20) µmol/l
occurring 60min after protein ingestion (P< 0·0001). Similarly,
MYC80 resulted in an increase in serum uric acid concentrations
by 30min (P< 0·01) with levels again peaking at 60min (at 378
(SEM 13) µmol/l; P< 0·0001) and, despite then decreasing back
towards fasting levels, remaining elevated throughout the entire
postprandial period (P< 0·05).
Whole body energy expenditure
Resting 24 h energy expenditure in the fasting state and during
the early (0–2 h) and late (2–4 h) postprandial period following
the ingestion of dietary protein is displayed in Fig. 6. Fasting
24 h energy expenditure was equivalent between visits (MLK20,
9·9 (SEM 0·4) MJ; MYC20, 9·4 (SEM 0·4) MJ; MYC40, 9·8 (SEM 0·5)
MJ; MYC60, 9·3 (SEM 0·3) MJ; MYC80, 9·1 (SEM 0·5) MJ; P> 0·05).
Time (P< 0·05) and time× treatment interaction (P< 0·001)
effects were observed such that protein ingestion resulted in a
significant decrease in energy expenditure in MLK20 during the
late phase (P< 0·05), and an increase in energy expenditure in
the MYC60 condition during the early postprandial phase
(P< 0·0001) and in the MYC80 condition during both the early
(P< 0·0001) and late (P< 0·001) postprandial phases.
Appetite responses
In the fasting state, appetite scores were similar between all
conditions at approximately 62 (P> 0·05). Appetite score was
affected by protein ingestion (time effect; P< 0·0001) and
condition (treatment effect; P< 0·05), though only a trend for an
interaction between time and treatment was observed (inter-
action effect; P= 0·097). Specifically, all conditions showed a
reduced appetite score 30min following protein ingestion (all
P< 0·01) which persisted to 60min in MLK20 (P< 0·05) and
MYC20 (P< 0·01) conditions, and until 120min in the MYC80
condition (P< 0·001) before returning towards fasting levels.
Compared with fasting values, all conditions showed a sig-
nificantly greater appetite score for the final 60 (MLK20 and
MYC20 conditions; P< 0·01) or 90min (MYC40 and MYC60
conditions; P< 0·05) of the postprandial period, with the
exception of the MYC80 condition where this increase in
appetite was not evident. Fig. 7 depicts these data as fasting,
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Fig. 5. Serum uric acid (A and B) concentrations in the fasting state (t= 0) and at regular intervals during a 4-h postprandial period following the ingestion of 20 g milk
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mean early (30–120min) and mean late (150–240min) appetite
responses.
Plasma biochemistry profile
Plasma clinical biochemistry profiles are reported in Table 3.
For written descriptions and statistical analyses of plasma
biochemistry responses please see the online Supplementary
material.
Discussion
In the present study we investigated the postprandial circulating
amino acid and insulin responses to mycoprotein ingestion. We
Early Late
–40
–30
–20
–10
0
10
20
MLK20 MYC20 MYC40 MYC60 MYC80
Ap
pe
tit
e 
sc
or
e 
(ch
an
ge
 fro
m 
fas
tin
g)
* *
*
*
*
*
* *
*
MLK20 MYC20 MYC40 MYC60 MYC80
Fig. 7. Change (from fasting) in appetite score during the early (i.e. 0–2 h) and
late (i.e. 2–4h) phases of a 4-h postprandial period following the ingestion of
20 g milk protein (MLK20), or 20 g (MYC20), 40 g (MYC40), 60 g (MYC60) or
80 g (MYC80) mycoprotein in healthy, young men (n 12). Values are means,
with their standard errors represented by vertical bars. Data were analysed with
a two-way repeated measures ANOVA and Bonferroni post hoc tests applied to
locate individual differences: * Significant change from fasting levels.
0
1000
2000
3000
R
es
tin
g 
en
er
gy
 e
xp
en
di
tu
re
 (k
ca
l/2
4 
h)
MLK20 MYC20 MYC40 MYC60 MYC80
a
b
a
a
a
Fig. 6. Resting energy expenditure in the fasting ( ) state and during the early
( ) (i.e. 0·2h) and late ( ) (i.e. 2–4h) phases of a 4-h postprandial period
following the ingestion of 20 g milk protein (MLK20), or 20 g (MYC20), 40 g
(MYC40), 60 g (MYC60) or 80 g (MYC80) mycoprotein in healthy, young men
(n 12). Values are means, with their standard errors represented by vertical
bars. Data were analysed with a two-way repeated measures ANOVA and
Bonferroni post hoc tests applied to locate individual differences: a and b
indicate value different from corresponding fasting or early postprandial value,
respectively. To convert kcal to kJ, multiply by 4·184.
Ta
b
le
3.
P
la
sm
a
cl
in
ic
al
ch
em
is
tr
y
pr
of
ile
s
in
th
e
fa
st
in
g
st
at
e
an
d
av
er
ag
e
va
lu
es
of
sa
m
pl
es
co
lle
ct
ed
du
rin
g
th
e
ea
rly
(0
–
2
h)
an
d
la
te
(2
–
4
h)
po
st
pr
an
di
al
pe
rio
ds
fo
llo
w
in
g
th
e
in
ge
st
io
n
of
20
g
m
ilk
pr
ot
ei
n
(M
LK
20
),
or
20
g
(M
Y
C
20
),
40
g
(M
Y
C
40
),
60
g
(M
Y
C
60
)
or
80
g
(M
Y
C
80
)
m
yc
op
ro
te
in
in
he
al
th
y,
yo
un
g
m
en
(n
12
)
(M
ea
n
va
lu
es
w
ith
th
ei
r
st
an
da
rd
er
ro
rs
)
Fa
st
in
g
E
ar
ly
po
st
pr
an
di
al
La
te
po
st
pr
an
di
al
M
LK
20
M
Y
C
20
M
Y
C
40
M
Y
C
60
M
Y
C
80
M
LK
20
M
Y
C
20
M
Y
C
40
M
Y
C
60
M
Y
C
80
M
LK
20
M
Y
C
20
M
Y
C
40
M
Y
C
60
M
Y
C
80
P
ar
am
et
er
s
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
M
ea
n
S
E
M
pH
7·
56
0·
01
7·
56
0·
01
7·
56
0·
01
7·
57
0·
01
7·
57
0·
01
7·
55
0·
01
7·
56
0·
01
7·
56
0·
01
7·
55
0·
01
7·
55
*
0·
01
7·
56
0·
01
7·
55
0·
01
7·
54
0·
01
7·
54
*
0·
01
7·
57
0·
01
N
a+
(m
m
ol
/l)
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
13
7
1
K
+
(m
m
ol
/l1
)
4·
3
0·
1
4·
3
0·
1
4·
2
0·
1
4·
1
0·
1
4·
2
0·
1
4·
2
0·
1
4·
2
0·
1
4·
2
0·
1
4·
1
0·
1
4·
2
0·
1
4·
0*
0·
1
4·
1
0·
1*
4·
1
0·
1
4·
1
0·
1
4·
1
0·
1
C
l−
(m
E
q/
l1
)
10
8·
4
0·
5
10
8·
3
0·
4
10
8·
0
0·
3
10
8·
0
0·
3
10
7·
9
0·
3
10
7·
2*
0·
3
10
7·
7
0·
3
10
7·
6
0·
3
10
7·
4
0·
5
10
7·
4
0·
3
10
7·
5*
0·
2
10
7·
9
0·
3
10
7·
5
0·
2
10
7·
6
0·
3
10
8
0·
3
C
a2
+
(m
m
ol
/l1
)
1·
17
0·
01
1·
16
0·
01
1·
17
0·
01
1·
17
0·
01
1·
17
0·
01
1·
18
*
0·
01
1·
17
0·
01
1·
17
0·
01
1·
17
0·
01
1·
18
*
0·
01
1·
19
*
0·
01
1·
17
0·
01
1·
17
0·
01
1·
17
0·
01
1·
17
†
0·
01
M
g2
+
(m
m
ol
/l)
0·
52
0·
01
0·
53
0·
01
0·
54
0·
01
0·
52
0·
01
0·
53
0·
01
0·
53
0·
01
0·
54
0·
01
0·
54
0·
01
0·
54
*
0·
01
0·
55
*
0·
01
0·
53
0·
01
0·
54
*
0·
01
0·
55
0·
01
0·
55
*
0·
01
0·
54
0·
01
G
lu
co
se
(m
m
ol
/l)
5·
5
0·
1
5·
4
0·
2
5·
5
0·
1
5·
4
0·
1
5·
4
0·
1
5·
3
0·
1
5·
4
0·
1
5·
5
0·
1
5·
5
0·
1
5·
4
0·
1
5·
2*
†
0·
1
5·
2*
†
0·
1
5·
3*
†
0·
1
5·
3†
0·
1
5·
4
0·
1
La
ct
at
e
(m
m
ol
/l)
0·
69
0·
07
0·
76
0·
10
0·
71
0·
05
0·
68
0·
07
0·
73
0·
08
0·
75
0·
08
0·
61
*
0·
05
0·
64
0·
06
0·
67
0·
06
0·
72
0·
06
0·
57
†
0·
05
0·
61
*
0·
04
0·
57
*
0·
04
0·
57
0·
05
0·
61
0·
05
U
re
a
(m
m
ol
/l)
5·
6
0·
3
5·
6
0·
4
5·
7
0·
3
5·
5
0·
3
5·
3
0·
3
5·
7
0·
3
5·
5
0·
3
5·
7
0·
3
5·
6
0·
3
5·
7*
0·
3
5·
4*
†
0·
3
5·
3*
†
0·
3
5·
7
0·
2
5·
8
0·
3
6·
0*
†
0·
3
C
re
at
in
in
e
(µ
m
ol
/l)
70
3
72
3
69
3
69
2
71
3
69
3
69
2
68
3
68
2
69
*
3
68
*
2
69
*
2
68
2
68
1
68
*
3
T
C
O
2
(m
E
q/
l)
24
·1
0·
3
23
·7
0·
4
23
·8
0·
3
23
·6
0·
4
24
·4
0·
4
24
·4
0·
3
23
·7
0·
3
23
·8
0·
4
23
·6
0·
4
24
·4
0·
4
24
·2
0·
3
23
·7
0·
4
24
·0
0·
3
23
·6
0·
4
23
·3
*†
0·
4
U
re
a:
cr
ea
tin
in
e
82
6
78
6
85
7
82
6
77
6
85
6
80
5
86
7
84
5
83
*
7
82
6
77
4
85
7
86
5
91
*
6
O
sm
ol
al
ity
(m
O
/k
g)
27
5
1
27
4
1
27
6
1
27
4
1
27
4
1
27
5
1
27
4
1
27
4
1
27
4
1
27
6
1
27
5
1
27
5
1
27
5
1
27
5
1
27
5
1
*
S
ig
ni
fic
an
t
di
ffe
re
nc
e
to
co
rr
es
po
nd
in
g
fa
st
in
g
va
lu
e.
†
S
ig
ni
fic
an
t
di
ffe
re
nc
e
to
co
rr
es
po
nd
in
g
ea
rly
po
st
pr
an
di
al
ph
as
e
va
lu
e.
Mycoprotein bioavailability dose–response 9
https://doi.org/10.1017/S0007114517002409
Downloaded from https://www.cambridge.org/core. University of Exeter, on 11 Oct 2017 at 07:50:54, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
assessed mycoprotein both in comparison with a more typical
animal-derived protein (milk protein), and in a dose–response
manner, in young healthy men. Mycoprotein ingestion resulted
in equivalent 4 h postprandial availability of serum insulin, and
plasma total, essential, non-essential and branched chain amino
acids when compared with milk protein. Mycoprotein, how-
ever, resulted in slower (and lower) peak plasma postprandial
amino acid and insulin concentrations, likely explained by
delayed digestion and absorption kinetics as a result of the high
fibre content. Increasing the ingested dose of mycoprotein
resulted in a corresponding increase in plasma amino acid
availability and augmented the serum insulin response, with
evidence to suggest these responses begin to plateau at a dose
of 60–80 g.
We first compared the response of a ‘mass matched’ meal-
like bolus of mycoprotein v. milk protein (i.e. MLK20 v.
MYC20). Milk protein was selected as a reference protein due to
its prevalence as a protein rich food (i.e. not a supplement)
within most diets, as well as commonly studied as a near ‘gold
standard’ protein source with respect to muscle protein ana-
bolism(40,41). Despite the practical relevance of this comparison,
due to its high fibre content, mycoprotein is <50% protein
(Table 2). Consequently, the greater plasma amino acid and
insulin responses following mass matched milk protein inges-
tion (Fig. 2–4) were not surprising. When comparing milk and
mycoprotein on a protein matched basis (i.e. MLK20 v. MYC40)
the bioavailability of all amino acids (Fig. 2–3) and insulin
(Fig. 4) were equivalent between conditions. Worthy of note,
the similar branched chain amino acid and leucine load
between the two proteins became equivalently available over
the 4 h postprandial period. By way of comparison, previous
investigations of other plant-based proteins (soy and wheat)
have shown that their ingestion results in lower essential amino
acid and leucine bioavailability compared with milk-derived
(whey and/or casein) proteins on a gram for gram basis(8,39).
Collectively, and within the context of previous studies exam-
ining the muscle anabolic responsiveness to milk protein(40,41),
our data infer that a 40-g bolus of mycoprotein provides
sufficient hyperaminoacidaemia (and insulinaemia) to mount a
robust muscle protein synthetic response in healthy individuals.
The speed and magnitude of the postprandial plasma amino
acid (and leucine in particular) peak has been highlighted as a
key parameter dictating the postprandial muscle protein synthetic
response(22,37,42). The ingestion of milk protein resulted in a more
rapid rise in plasma essential amino acids (30 v. 120min,
respectively) and leucine (30 v. 90min, respectively) compared
with 40 g mycoprotein. In addition, both of these responses were
also of a greater magnitude, suggesting the milk may have the
capacity to mount a greater muscle protein synthetic response.
The differential digestion and absorption kinetics are likely
explained by the additional fibre contained within mycoprotein,
delaying gastric emptying(43) and/or intestinal amino acid
absorption(44). Indeed, given the almost identical leucine and
branched chain amino acid loads (and bioavailability) of myco-
protein, any superior anabolic potential of milk is likely directly
attributable to the fibre induced slowing of the digestion and
absorption kinetics. Presumably as a direct result of this, when
matched for protein content, mycoprotein also led to a more
modest insulin response compared with milk protein. It has
previously been shown that insulin is permissive, rather than
stimulatory, in mediating postprandial muscle protein synthesis
rates(24,45). That is to say, any rise from basal insulin levels in the
postprandial state seems sufficient to facilitate the muscle protein
synthetic response, at which point amino acids alone provide the
key nutritional signal dictating the magnitude of response(24,45,46).
As such, the insulin response to the ingestion of 40 g mycoprotein
would be unlikely to limit postprandial muscle protein synthesis
rates. It should be noted, however, that a greater insulin response
(for instance with increasing dose or with carbohydrate
co-ingestion) may further inhibit postprandial proteolysis and
thus contribute to the net anabolic response(24).
Despite the faster digestion absorption kinetics of milk
protein, the relevance of rapid hyperaminoacidaemia to the
anabolic response has recently been challenged(47). Mitchell
et al. observed equivalent muscle protein synthetic responses
following essential amino acid administration ingested either as
a single 15 g bolus (i.e. rapid hyperaminoacidaemia) or in a
pulsatile fashion (4× 3·75 g every 45min; i.e. slower, less pro-
nounced hyperminoacidaemia), albeit in older men. These
findings suggest that the overall amount and subsequent bio-
availability of essential amino acids within a dietary protein
source are of more relevance in determining the magnitude of
the muscle protein synthetic response. This underlines the
importance of our present finding that dietary amino acids
derived from mycoprotein are equivalently bioavailable when
compared on a gram for gram basis with those derived from
milk protein (which is typically not the case concerning plant-
based proteins(8,9,39)). Furthermore, in Mitchell et al.’s study,
though the 4-h period during which muscle protein synthesis
rates were determined provided equivalent responses between
bolus and pulse feeding, the final 2 h of the experimental period
favoured the pulse approach, presumably due to the more
sustained amino acid availability. As such, an important ques-
tion remains: would the more slowly digested/absorbed, more
sustained availability of amino acids (and insulin) following
mycoprotein result in improved muscle anabolism compared
with ‘faster’ proteins, particularly over more prolonged post-
prandial periods?
Coupled with comparing mycoprotein with a reference
animal-derived protein, we also sought to assess the impact
of graded doses of mycoprotein. We observed a clear
dose–response relationship, with 60> 40> 20 g regarding total
postprandial amino acid and insulin availability and magnitude
of responses. Increasing the dose of mycoprotein up to 60 g did
not delay the rise to peak in plasma concentrations, and in
the case of total amino acids, non-essential amino acids and
leucine, appeared to expedite the responses (30, 15 and 30min,
respectively, compared with 45–90min for other mycoprotein
conditions). Despite a more rapid peak than other mycoprotein
conditions, 60 g led to sustained hyperaminoacidaemia for 3–4 h
post ingestion, which would provide the relevant signalling
amino acids as well as substrate to enable a sustained muscle
protein synthetic response. The 60 g bolus also contains close to
what is considered the optimal leucine content to facilitate a
maximal muscle protein synthetic response (i.e. ≥2·5 g)(9,21,22),
and this became available rapidly and to an overall greater
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degree during the 4-h postprandial period compared with lower
doses of mycoprotein or milk protein. It is generally regarded
that a marked acceleration of whole body amino acid oxidation
following protein ingestion is indicative of excessive amino acid
availability(48,49). Though amino acid oxidation rates were not
measured in this study, the absence of any rise in plasma urea
concentrations following the 60 g condition (Table 3) suggests
minimal changes, and that the body protein pool would
primarily be making use of this dietary protein for synthetic
processes. In support of this assertion, studies that have
established an approximate dose of 20 g whey or egg protein as
sufficient for a maximal stimulation of muscle protein synthesis
rates(27,50) have generally observed minimal increases in amino
acid oxidation rates and plasma urea concentrations/production
rates at these doses, with increases only evident with increasing
amounts. Collectively, these data suggest that the ingestion of
60 g mycoprotein (i.e. 27 g protein) would be ample for the
optimal stimulation of muscle protein synthesis rates in healthy
young men.
Increasing the dose of mycoprotein ingestion from 60 to 80 g
did not substantially alter postprandial amino acid availability.
Indeed, no amino acid (or subgroup) showed a significantly
greater AUC in the 80 g compared with the 60 g condition, and
various amino acid peaks exhibiting delayed kinetics in the 80 g
condition. Plasma urea concentrations rose sharply in both the
early (8%) and late (13% ) postprandial periods following the
ingestion of 80 g mycoprotein (Table 3), implying this large
amount of protein was an ‘overload’ and required a marked rise
in oxidation to restore blood homeostasis. This is in keeping
with previous studies that have established similar metabolic
effects of protein boluses in excess of what is required for
optimally stimulating muscle protein synthesis rates(48,51).
Coupled with this, ordinary blood biochemistry was altered
substantially (and differentially compared with other condi-
tions) only in MYC80, also implying this was an excessive dose
to support normal metabolism. Taken together, it seems likely
that increasing the dose from 60 to 80 g of mycoprotein would
not convey any benefits with respect to the stimulation of
muscle protein synthesis rates in healthy young men. It should
be noted, however, that most postprandial plasma amino acid
parameters (with the exception of total essential amino acids)
and insulin levels were numerically higher when compared
with the 60 g mycoprotein condition, and remained consistently
elevated for the entire 4 h postprandial period (selected as a
typical ‘real world’ postprandial period before subsequent meal
consumption) in the 80 g mycoprotein condition only. This may
be of relevance when considering postprandial periods
expected to extend beyond 4 h. For example, pre-sleep protein
is an increasingly popular strategy for augmenting muscle
protein synthesis rates during the extended overnight
period(52–56), an approach also shown to augment the adaptive
response to prolonged training(57). Likely as a consequence of
this extended overnight postprandial period, these studies have
suggested that ‘slower proteins’ capable of facilitating more
prolonged hyperaminoacidaemia, and in relatively larger doses,
may be optimal for the stimulation of muscle protein synthesis
rates. Consequently, this would provide a rationale for why a
larger dose of mycoprotein (e.g. 80 g) may be a suitable dietary
protein source to use as a pre-sleep strategy aimed at optimising
overnight muscle protein synthesis rates. Additional con-
siderations for the potential utility of the 80 g condition involve
situations where the dose–response relationship is likely shifted
to the right; for instance the presence of anabolic resistance
to dietary protein with ageing(58) or disuse(59).
Previous work has shown the ingestion of large quantities of
nucleotides to result in acute hyperuricaemia above clinically
accepted levels(29,30,60), which has raised concerns over
the chronic consumption of nucleotide containing protein
sources(50,61). Mycoprotein (and other plant-based protein
sources) generally contain a lower nucleotide load compared
with meat/fish-derived protein sources(62). In keeping with this,
we report that the ingestion of moderate doses of mycoprotein
(≤40 g) does not modulate serum uric acid concentrations
(Fig. 5) and, in the case of the 20 g dose, actually had a modest
and transient lowering effect. The ingestion of 60 and 80 g
resulted in elevated serum uric acid concentrations and, for the
latter, this persisted for the 4-h postprandial period. These levels
increased from approximately 350–370 to 380–390 µmol/l and
thus did not approach a clinically significant concentration for
men (i.e. >420 µmol/l)(28,60). It should also be noted that even
with serum uric acid levels >420 µmol/l, this is only a recog-
nised predictor of gout and/or metabolic complications when
existing chronically and in the fasting state, rather than during
daily oscillations in response to nutrition(28). Indeed, while
circulating uric acid levels are elevated with gout, gout per se
does not necessarily lead to elevated serum uric acid(28). As
such, it remains to be established if hyperuricaemia is a cause or
consequence of the clinical condition(s) that it predicts.
Research has highlighted the key role that dietary protein
plays in weight management and the promotion of cardio-
metabolic health(63). Central to this role are the thermogenic
and satiating properties that dietary protein possesses(63). In
line, we report that mycoprotein mounts a robust thermogenic
effect, which we specifically detected at the 60 and 80 g doses
(Fig. 6), and a satiating effect under all conditions, comparable
to milk protein and sustained over the entire 4 h postprandial
period only in the 80 g condition (Fig. 7). It could be speculated
that, if consumed in sufficient quantities to elicit optimal
aminoacidaemia to support muscle protein anabolism, any
concerns with additional energy intake (when considering
weight maintenance and metabolic health) would be offset by
these satiating and thermogenic properties. Clearly further
research is warranted to investigate the role of mycoprotein not
only in muscle anabolism, but also in supporting weight
maintenance and metabolic health.
To summarise our present data into practical relevance,
based on the observed bioavailability we speculate that the
ingestion of 40 g mycoprotein (i.e. 18 g total protein) would be
sufficient to mount a robust muscle protein synthetic response,
with the ingestion of 60 g mycoprotein (i.e. 27 g total protein)
likely necessary to provide an optimal anabolic response. It is
unlikely that consuming in excess of 60 g would confer any
further benefits in healthy individuals. We conclude that
mycoprotein represents a bioavailable and insulinotropic non-
animal-derived dietary protein. Consumed in sufficient quan-
tities, mycoprotein would be expected to support skeletal
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muscle anabolism and reconditioning and therefore have clear
utility to muscle health in a variety of populations.
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